Meet Glenn™, Insight Medbotics' Next-Generation MRI-Compatible Robotics System for Prostate Cancer Care

System leveraging 510k-cleared IGAR technology attracts growing interest from urologists across U.S. hospitals and private practices

TORONTO, Sept. 18, 2025 /PRNewswire/ - Insight Medbotics, an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics, is previewing a new product direction for its next-generation robotics system. Glenn™is being designed to help more urologists treat prostate cancer with greater precision within an MRI scanner.

Glenn leverages the company's previous work on MRI-compatible and clinically demonstrated robotics in breast biopsy; the IGAR robotics system is the only robotics system designed for use with MRI scanners to receive 510(k) clearance from the FDA. The new robot digitizes the entire care pathway, offering data-driven clinical insight in ways that haven't been possible before, giving urologists intuitive MRI access while removing the guesswork of traditional ultrasound guidance.

"As we demonstrate the system to practicing urologists and collect their feedback on its design, they intuitively grasp its potential and express interest in acquiring it once it's available," says CEO and Board of Directors member Fazila Seker. "The quick, precise, needle-based procedures it facilitates, such as biopsies and focal therapies, are of particular interest. They also noted that it would eliminate the need for rectal probes, which some said their patients wish to avoid."

Over the last year, the company has recruited several leading urologists to its clinical advisory board, and appointed Dr. Edward Matsumoto to the Board of Directors. "Working with clinicians whose needs drive our design decisions is a tremendous gift," says Seker. "Having access to these key opinion leaders help us advance the standard of care for prostate cancer patients through new technology and surgical education. I'm honored that they value us as a partner in bringing a better, more consistent standard of care to their patients."

When given the chance to see Glenn's current demonstration, Dr. Alexander Kutikov, chair of the Department of Urology at Temple Health's Fox Chase Cancer Centre, said: "The robot knows exactly where in the prostate the biopsies were taken from, so if and when focal therapy is delivered, it would be directed precisely at the site of the cancer. That's incredibly powerful."

"As we develop full functionality with our prostate platform, our focus is addressing urologists' need to access MRI for their patients," said Seker. "That means advancing Glenn toward regulatory approval, beginning with the U.S. market and following in Canada and other countries."

Glenn™is currently under development and is not approved by any regulatory body. The system is not for sale in any international market. 

About Insight Medbotics
Insight Medbotics is an interventional oncology company advancing precision in cancer care through its MRI-compatible robotics. IGAR, the company's flagship MRI-compatible robot, has been clinically demonstrated. As the only company to receive a FDA 510(k) clearance for use of a robot with an MRI, Insight Medbotics is now advancing the technology to improve the standard of precision in prostate cancer care.

View original content to download multimedia:https://www.prnewswire.com/news-releases/meet-glenn-insight-medbotics-next-generation-mri-compatible-robotics-system-for-prostate-cancer-care-302560474.html

SOURCE Insight Medbotics